Rapamycin: Meet the new CEO tasked with taking SA drug developer's first product to market
Rapamycin Holdings' new leader will oversee a major fundraising round needed to position the company for commercial success.
Read full article »
Rapamycin manufactures and commercializes sirolimus-based drugs for the treatment of dementia, cancer and autoimmune diseases.
Read more